Item 5.02 Departures of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In connection with the previously announced appointment of Paul K. Wotton as
Chief Executive Officer and President of Advanced Cell Technology, Inc. (the
"Company"), the Board of Directors (the "Board") of the Company appointed Dr.
Wotton to serve as a director, effective July 31, 2014, until the next annual
meeting of the Company's stockholders, where he will stand for election. The
appointment of Dr. Wotton as a director brings the size of the Company's Board
to six members.
At the time of this disclosure, Dr. Wotton was named to the pricing committee of
the Board; no other committee assignments are contemplated at this time. There
are no family relationships between Dr. Wotton and any director or executive
officer of the Company. Other than as provided in the employment agreement
between the Company and Dr. Wotton dated as of June 18, 2014 filed as Exhibit
10.1 to the Company's Current Report on Form 8-K filed on June 24, 2014, Dr.
Wotton has no direct or indirect material interest in any transaction required
to be disclosed pursuant to Item 404(a) of Regulation S-K.